Vascular Pathology in Alzheimer Disease: Correlation of Cerebral Amyloid Angiopathy and Arteriosclerosis/lipohyalinosis with Cognitive Decline
Overview
Affiliations
Sporadic, late-onset Alzheimer disease (AD) constitutes the most frequent cause of dementia in the elderly population. AD-related pathology is often accompanied by vascular changes. The predominant vascular lesions in AD are cerebral amyloid angiopathy (CAA) and arteriosclerosis/lipohyalinosis (AS/LH). The present study was carried out to examine the coincidence of these small vessel pathologies during the development of cognitive deficits, amyloid beta-protein (A beta) deposition, and neurofibrillary tangle (NFT) formation in sporadic late-onset AD. We correlated the clinical dementia rating (CDR) score, the sequential extension of AD-related A beta deposition into different parts of the brain, and the extension of NFTs to involve more brain regions with the distribution of CAA and AS/LH in 52 human autopsy brains. The extension of CAA and AS/LH to involve different areas of the brain was associated with a rise of CDR scores and an increase in the extension of A beta deposition and NFT generation. AD cases showed a higher number of regions with CAA and AS/LH compared to nondemented patients with AD-related pathology and controls. Moreover, we demonstrated a hierarchical sequence in which the different regions of the brain exhibited CAA and AS/LH-affected vessels, allowing the distinction of 3 stages in the development of CAA and AS/LH. The first stage of CAA involved leptomeningeal and neocortical vessels. The second stage was characterized by additional A beta deposition in allocortical and midbrain vessels. Finally, in a third stage, CAA was observed in the basal ganglia, the thalamus, and in the lower brainstem. In contrast, AS/LH initially affected the basal ganglia in stage A. In stage B this pathology made inroads into the deep white matter, the leptomeningeal arteries of the cortex, the cerebellum, and into the thalamus. Stage C was characterized by AS/LH in brainstem vessels. Our results demonstrate widespread CAA and AS/LH to be associated with the development of cognitive deficits in AD. A combination of both CAA and AS/LH may, therefore, contribute to neurodegeneration in AD. These data also suggest that small vessel disease due to arteriosclerosis and fibrolipohyalinosis is a potential target for the treatment of AD.
Taghvaei M, Dolui S, Sadaghiani S, Shakibajahromi B, Brown C, Khandelwal P Alzheimers Dement. 2024; 21(1):e14382.
PMID: 39625074 PMC: 11772719. DOI: 10.1002/alz.14382.
Barnes C, Permenter M, Vogt J, Chen K, Beach T J Comp Neurol. 2024; 532(9):e25670.
PMID: 39315417 PMC: 11451939. DOI: 10.1002/cne.25670.
Shinto L, Murchison C, Silbert L, Dodge H, Lahna D, Rooney W JAMA Netw Open. 2024; 7(8):e2426872.
PMID: 39088212 PMC: 11294966. DOI: 10.1001/jamanetworkopen.2024.26872.
Advancements and Challenges in Antiamyloid Therapy for Alzheimer's Disease: A Comprehensive Review.
Abdi Beshir S, Hussain N, Menon V, Al Haddad A, Al Zeer R, Elnour A Int J Alzheimers Dis. 2024; 2024:2052142.
PMID: 39081336 PMC: 11288696. DOI: 10.1155/2024/2052142.
Shirzadi Z, Schultz A, Properzi M, Yaari R, Yau W, Brickman A J Prev Alzheimers Dis. 2024; 11(4):869-873.
PMID: 39044495 PMC: 11266366. DOI: 10.14283/jpad.2024.139.